UK–South Asian patients’ experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis
Authors Kumar K, Raizada SR, Mallen CD, Stack RJ
Received 10 October 2017
Accepted for publication 14 December 2017
Published 4 April 2018 Volume 2018:12 Pages 489—497
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Johnny Chen
Kanta Kumar,1,2 Sabrina R Raizada,3 Christian D Mallen,4 Rebecca J Stack5
1Faculty of Biology, Medicine and Health, School of Health Sciences, The University of Manchester, Manchester, UK; 2Central Manchester University Hospitals Foundation Trust, Manchester, UK; 3The Royal Wolverhampton NHS Trust, Wolverhampton, UK; 4Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Staffordshire, UK; 5School of Social Sciences, Nottingham Trent University, Nottingham, UK
Background: Rheumatoid arthritis (RA) causes painful joint inflammation and is incurable, but treatments control RA. Drug regimens are complex, and patients often do not take their medication as expected. Poor medication adherence can lead to poorly controlled disease and worse patient outcomes. Biologics treatments are expensive and require full engagement from patients. We have previously shown that patients from Black ethnic minority backgrounds do not fully engage into treatment plan. This study explored the patients’ experiences in and satisfaction toward receiving information about biologics and future support preferences in South Asian patients with RA.
Methods: Twenty South Asian patients with RA from Royal Wolverhampton Hospitals NHS Trust and Central Manchester University Hospitals NHS Foundation Trust participated in individual semistructured interviews. Interviews were transcribed and data were analyzed by using thematic analysis approach.
Results: Four overarching themes describe the patients’ experience in and satisfaction toward receiving information on biologics: 1) current provision of information regarding the “biologics journey” and understanding of RA: in this theme, non-English-speaking patients expressed heightened anxiety about stepping up to biologics; 2) experience and perceptions of biologics: many patients were positive about the biologic experience; however, there were patient-perceived delays in getting on to the biologics; 3) factors influencing willingness to try biologics: in this theme, a number of factors were identified including seeking advice from doctors abroad; and 4) recommendations on the desired information to fully understand the use of biologics: some patients valued group discussions, while others suggested receiving RA and biologic information through a video interaction.
Conclusion: This novel study provides insight into South Asian RA patients’ experiences in and satisfaction toward receiving information about biologics. South Asian patients with RA reported a range of perceptions about biologics and support preferences, many of which may not be shared with the non-South Asian population.
Keywords: rheumatoid arthritis, biologic treatment, patient perceptions, illness beliefs, ethnicity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]